Abstract
Erythropoietin (EPO) is a pleiotropic type I cytokine that has been identified as a major endogenous tissue protective molecule. In response to injury, EPO and a distinct receptor are expressed with a characteristic temporal and spatial expression pattern. Together, these serve to limit injury and to initiate repair. Administration of EPO in the setting of injury has been shown to be beneficial in a multitude of preclinical models. However, translation into the clinic has been hampered by EPO’s adverse effects, including promotion of thrombosis. Recently, engineered molecules based on EPO’s structure–activity relationships have been developed that are devoid of hematopoietic effects. These compounds are promising candidates for treatment of a wide variety of acute and chronic diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jelkmann W (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78:183–205
Marti HH, Wenger RH, Rivas LA et al (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 8:666–676
Westenfelder C, Biddle DL, Baranowski RL (1999) Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55:808–820
Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269:19488–19493
Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76:105–116
Brines ML, Ghezzi P, Keenan S et al (2000) Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97:10526–10531
Erbayraktar S, Grasso G, Sfacteria A et al (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 100:6741–6746
Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1–14
Pinto JP, Ribeiro S, Pontes H et al (2008) Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood 111:5727–5733
Brines M, Cerami A (2008) Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 264:405–432
Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87:5978–5982
Masuda S, Nagao M, Takahata K et al (1993) Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268:11208–11216
Imai N, Higuchi M, Kawamura A et al (1990) Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem 194:457–462
Cheetham JC, Smith DM, Aoki KH et al (1998) NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat Struct Biol 5:861–866
Leist M, Ghezzi P, Grasso G et al (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239–242
Brines M, Grasso G, Fiordaliso F et al (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 101:14907–14912
Lopez AF, Hercus TR, Ekert P et al (2010) Molecular basis of cytokine receptor activation. IUBMB Life 62:509–518
Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA (1997) The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood 90:1867–1873
Brines M, Cerami A (2012) The receptor that tames the innate immune response. Mol Med 18(1):486–496
Corwin HL, Gettinger A, Fabian TC et al (2007) Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357:965–976
Brines M, Patel NS, Villa P et al (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105:10925–10930
Nogawa-Kosaka N, Hirose T, Kosaka N et al (2010) Structural and biological properties of erythropoietin in Xenopus laevis. Exp Hematol 38:363–372
Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609:29–35
Mahmood A, Lu D, Qu C et al (2007) Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 107:392–397
van der Meer P, Lipsic E, Henning RH et al (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46:125–133
Erbayraktar Z, Erbayraktar S, Yilmaz O, Cerami A, Coleman T, Brines M (2009) Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med 15:235–241
Su KH, Shyue SK, Kou YR et al (2011) Beta common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J Cell Physiol 226(12):3330–3339
Sautina L, Sautin Y, Beem E et al (2010) Induction of nitric oxide by erythropoietin is mediated by the beta common receptor and requires interaction with VEGF receptor 2. Blood 115:896–905
Disclosure of Interest
The authors are officers of Araim Pharmaceuticals and currently hold stocks/shares in the company.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Brines, M., Cerami, A. (2013). Erythropoietin and Engineered Innate Repair Activators. In: Ghezzi, P., Cerami, A. (eds) Tissue-Protective Cytokines. Methods in Molecular Biology, vol 982. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-308-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-308-4_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-307-7
Online ISBN: 978-1-62703-308-4
eBook Packages: Springer Protocols